Catalytic Wealth RIA LLC Has $936,000 Position in Stryker Co. (NYSE:SYK)

Catalytic Wealth RIA LLC lifted its position in Stryker Co. (NYSE:SYK - Free Report) by 181.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,591 shares of the medical technology company's stock after purchasing an additional 1,669 shares during the quarter. Catalytic Wealth RIA LLC's holdings in Stryker were worth $936,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Chartwell Investment Partners LLC grew its holdings in shares of Stryker by 5.3% in the 3rd quarter. Chartwell Investment Partners LLC now owns 34,263 shares of the medical technology company's stock worth $12,378,000 after purchasing an additional 1,722 shares during the last quarter. Ashton Thomas Securities LLC grew its holdings in shares of Stryker by 11.2% in the 3rd quarter. Ashton Thomas Securities LLC now owns 1,158 shares of the medical technology company's stock worth $418,000 after purchasing an additional 117 shares during the last quarter. Arrow Financial Corp grew its holdings in shares of Stryker by 0.4% in the 3rd quarter. Arrow Financial Corp now owns 13,521 shares of the medical technology company's stock worth $4,885,000 after purchasing an additional 55 shares during the last quarter. Mesirow Financial Investment Management Inc. lifted its position in Stryker by 1.4% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 18,136 shares of the medical technology company's stock worth $6,554,000 after buying an additional 253 shares in the last quarter. Finally, XML Financial LLC lifted its position in Stryker by 7.1% during the 3rd quarter. XML Financial LLC now owns 3,100 shares of the medical technology company's stock worth $1,120,000 after buying an additional 205 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of SYK traded up $2.78 during trading hours on Monday, hitting $378.74. 396,410 shares of the company were exchanged, compared to its average volume of 1,250,590. The company has a market cap of $144.38 billion, a price-to-earnings ratio of 40.30, a P/E/G ratio of 2.83 and a beta of 0.91. Stryker Co. has a fifty-two week low of $276.60 and a fifty-two week high of $381.54. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The firm's fifty day moving average is $361.46 and its 200 day moving average is $345.77.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Stryker's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.46 EPS. On average, equities analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares of the company's stock, valued at approximately $36,879,954.90. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the sale, the vice president now owns 10,042 shares of the company's stock, valued at $3,685,213.16. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 67,381 shares of company stock valued at $24,825,275. 5.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts recently issued reports on SYK shares. Stifel Nicolaus reduced their price target on shares of Stryker from $375.00 to $365.00 and set a "buy" rating on the stock in a research report on Wednesday, July 31st. Citigroup upped their target price on shares of Stryker from $406.00 to $411.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. UBS Group raised their price target on shares of Stryker from $366.00 to $370.00 and gave the stock a "neutral" rating in a research note on Wednesday, October 30th. StockNews.com cut shares of Stryker from a "buy" rating to a "hold" rating in a research note on Wednesday, November 6th. Finally, Needham & Company LLC raised their price target on shares of Stryker from $393.00 to $409.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Stryker presently has a consensus rating of "Moderate Buy" and a consensus target price of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.